Elanco Animal Health Incorporated (ELAN) Free cash flow
- Free cash flow · 12 months (USD): Value $379.00M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value 7.55%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $379.00M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $617.00M − $238.00M ≈ $379.00M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 7.55% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $379.00M ÷ $5.02B × 100 ≈ 7.55% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $617.00M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | -3.10× | Operating cash flow / net income. Period ending 2026-06-30. $617.00M ÷ $-199.00M ≈ -3.10× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 617.00M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 238.00M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 379.00M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 5.02B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -199.00M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $379.00M | (m) | $617.00M | $238.00M | (m) | $5.02B | (m) | $-199.00M | (m) | (m) | 7.55% | -3.10× |
| 2026-03-31 | $315.00M | (m) | $577.00M | $262.00M | (m) | $4.89B | (m) | $-242.00M | (m) | (m) | 6.44% | -2.38× |
| 2025-12-31 | $284.00M | (m) | $560.00M | $276.00M | (m) | $4.71B | (m) | $-232.00M | (m) | (m) | 6.02% | -2.41× |
| 2025-09-30 | $368.00M | (m) | $629.00M | $261.00M | (m) | $4.59B | (m) | $36.00M | (m) | (m) | 8.02% | 17.47× |
| 2025-06-30 | $361.00M | (m) | $572.00M | $211.00M | (m) | $4.48B | (m) | $434.00M | (m) | (m) | 8.05% | 1.32× |
| 2025-03-31 | $347.00M | (m) | $535.00M | $188.00M | (m) | $4.43B | (m) | $373.00M | (m) | (m) | 7.84% | 1.43× |
| 2024-12-31 | $394.00M | (m) | $541.00M | $147.00M | (m) | $4.44B | (m) | $338.00M | (m) | (m) | 8.88% | 1.60× |
| 2024-09-30 | $380.00M | (m) | $521.00M | $141.00M | (m) | $4.45B | (m) | $205.00M | (m) | (m) | 8.53% | 2.54× |
| 2024-06-30 | $425.00M | (m) | $557.00M | $132.00M | (m) | $4.49B | (m) | $-1.25B | (m) | (m) | 9.46% | -0.44× |
| 2024-03-31 | $278.00M | (m) | $418.00M | $140.00M | (m) | $4.37B | (m) | $-1.30B | (m) | (m) | 6.37% | -0.32× |
| 2023-12-31 | $131.00M | (m) | $271.00M | $140.00M | (m) | $4.42B | (m) | $-1.23B | (m) | (m) | 2.97% | -0.22× |
| 2023-09-30 | (m) | (m) | $127.00M | (m) | (m) | $4.37B | (m) | $-1.14B | (m) | (m) | (m) | -0.11× |
| 2023-06-30 | (m) | (m) | $118.00M | (m) | (m) | $4.32B | (m) | $-113.00M | (m) | (m) | (m) | -1.04× |
| 2023-03-31 | $231.00M | (m) | $369.00M | $138.00M | (m) | $4.44B | (m) | $-26.00M | (m) | (m) | 5.20% | -14.19× |
| 2022-12-31 | $315.00M | (m) | $452.00M | $137.00M | (m) | $4.41B | (m) | $-78.00M | (m) | (m) | 7.14% | -5.79× |
| 2022-09-30 | $525.00M | (m) | $662.00M | $137.00M | (m) | $4.54B | (m) | $-120.00M | (m) | (m) | 11.56% | -5.52× |
| 2022-06-30 | $426.00M | (m) | $562.00M | $136.00M | (m) | $4.65B | (m) | $-175.00M | (m) | (m) | 9.17% | -3.21× |
| 2022-03-31 | $272.00M | (m) | $399.00M | $127.00M | (m) | $4.75B | (m) | $-363.00M | (m) | (m) | 5.73% | -1.10× |
| 2021-12-31 | $357.00M | (m) | $483.00M | $126.00M | (m) | $4.76B | (m) | $-472.00M | (m) | (m) | 7.49% | -1.02× |
| 2021-09-30 | $-11.60M | (m) | $167.00M | $178.60M | (m) | $4.79B | (m) | $-698.10M | (m) | (m) | -0.24% | -0.24× |
| 2021-06-30 | (m) | (m) | $-34.00M | (m) | (m) | $4.55B | (m) | $-729.10M | (m) | (m) | (m) | 0.05× |
| 2021-03-31 | $-162.60M | (m) | $-23.00M | $139.60M | (m) | $3.86B | (m) | $-572.10M | (m) | (m) | -4.22% | 0.04× |
| 2020-12-31 | $-175.60M | (m) | $-41.00M | $134.60M | (m) | $3.27B | (m) | $-560.10M | (m) | (m) | -5.36% | 0.07× |
| 2020-09-30 | $71.40M | (m) | $178.20M | $106.80M | (m) | $2.92B | (m) | $-246.80M | (m) | (m) | 2.44% | -0.72× |
| 2020-06-30 | (m) | (m) | $329.50M | (m) | (m) | $2.80B | (m) | $-101.80M | (m) | (m) | (m) | -3.24× |
| 2020-03-31 | $95.30M | (m) | $220.30M | $125.00M | (m) | $3.00B | (m) | $-12.70M | (m) | (m) | 3.18% | -17.35× |
| 2019-12-31 | $83.70M | (m) | $224.10M | $140.40M | (m) | $3.07B | (m) | $67.90M | (m) | (m) | 2.73% | 3.30× |
| 2019-09-30 | $91.10M | (m) | $237.30M | $146.20M | (m) | $3.08B | (m) | $93.80M | (m) | (m) | 2.95% | 2.53× |
| 2019-06-30 | $231.80M | (m) | $361.60M | $129.80M | (m) | $3.07B | (m) | $144.00M | (m) | (m) | 7.54% | 2.51× |
| 2019-03-31 | $316.10M | (m) | $445.90M | $129.80M | (m) | $3.06B | (m) | $45.30M | (m) | (m) | 10.32% | 9.84× |
| 2018-12-31 | $352.80M | (m) | $487.30M | $134.50M | (m) | $3.07B | (m) | $86.50M | (m) | (m) | 11.50% | 5.63× |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-172.30M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-139.70M | (m) | (m) | (m) | (m) |
| 2017-12-31 | $75.20M | (m) | $173.80M | $98.60M | (m) | $2.89B | (m) | $-310.70M | (m) | (m) | 2.60% | -0.56× |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $45.60M | (m) | $155.90M | $110.30M | (m) | $2.91B | (m) | $-47.90M | (m) | (m) | 1.57% | -3.25× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |